araag2/HINT huggingface dataset:
Clinical trial NCT01046487 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: imatinib mesylate, cyclophosphamide (dosing level 1 ), imatinib mesylate, cyclophosphamide (dosing level 2), imatinib mesylate, cyclophosphamide (dosing level 3)
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Rare tumor

          -  metastatic disease or locally advanced disease, inoperable, with no standard treatment

          -  At least 28 days since the prior treatment

          -  Measurable disease with at least one measurable lesion

        Exclusion Criteria:

          -  Medullary insufficiency

          -  Cystitis, haemorrhagic cystitis

          -  Hepatic porphyria
Clinical trial NCT01381887 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, canagliflozin 300mg/placebo, canagliflozin 300mg/canagliflozin 150mg, canagliflozin 300mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with T2DM with inadequate glycemic control (based upon fasting glucose
             measurements >=130 mg/dL and <=250 mg/dL) on metformin monotherapy or on metformin in
             dual combination with other glucose lowering agents (sulphonylurea [SU] or a
             meglitinide or a dipeptidyl peptidase-4 [DPP-4] inhibitor) are eligible for enrollment
             in the study.

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy

          -  history of a severe hypoglycemic episode within 6 months before screening

          -  Has repeated (ie, 2 or more over a 1-week period) fasting plasma glucose (FPG) and/or
             fasting self-monitored blood glucose (SMBG) measurements >=250 mg/dL (13.88 mmol/L)
             during the pre-treatment phase, despite reinforcement of diet and exercise counseling

          -  History of or current illness considered to be clinically significant by the
             investigator
Clinical trial NCT02015676 (phase 1/phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab, paclitaxel, myocet
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  women 18-70 years of age;

          -  metastatic or locally advanced breast cancer;

          -  HER2 overexpression;

          -  >= 1 measurable lesion.

        Exclusion Criteria:

          -  prior treatment for advanced breast cancer;

          -  prior treatment with Herceptin;

          -  bone or central nervous system metastasis as the only site of disease;

          -  history of another malignancy (except basal cell skin cancer and cancer in situ of the
             uterine cervix, and contralateral breast cancer) within 5 years of study.
Clinical trial NCT01813955 (early phase 1, status: terminated)
Conditions: schizophrenia, cognitive deficits
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, R41.841, R41.81, G31.84, I69.315, I69.015, I69.115, I69.815
Drugs: papaverine or placebo
SMILES: COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
Reason stopped: 
    patient recruitment insufficient
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed Schizophrenia (WHO ICD 10)

          -  Treatment stable (no regulation in medicine for 6 weeks prior)

          -  Mono antipsychotic treatment

          -  No regular Antidepressants (PN accepted)

          -  No regular Benzodiazepines (PN accepted)

        Exclusion Criteria:

          -  Dependence syndrome

          -  Severe physical illness

          -  MRI incompatible, non removable objects above shoulders
Clinical trial NCT01213160 (phase 1, status: completed)
Conditions: cancer, advanced solid malignancies
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: azd4547
SMILES: COC1=CC(OC)=CC(CCC2=CC(NC(=O)C3=CC=C(C=C3)N3C[C@H](C)N[C@H](C)C3)=NN2)=C1
Eligibility criteria:

        Inclusion Criteria:

        - Japanese patients with advanced solid malignancies Over 25 years old Relatively good
        overall health other than cancer

        Exclusion Criteria:

        - Poor bone marrow function (not producing enough blood cells). Poor liver or kidney
        function. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
        swallow the IP or previous significant bowel resection.
Clinical trial NCT00315861 (phase 1, status: completed)
Conditions: ovarian cancer, endometrial cancer, cervical cancer, lung cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, N85.00, N85.01, N85.02, N99.85, M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, topotecan
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven advanced solid tumors

          -  Measurable or evaluable disease

          -  Age ≥ 18 years

          -  Karnofsky performance status ≥ 80% (ECOG 0 or 1)

          -  Adequate liver, bone marrow and kidney function

        Exclusion Criteria:

          -  More than 3 prior chemotherapy regimens in the metastatic setting

          -  Prior treatment with topotecan or pemetrexed

          -  Clinically significant third space fluid present at the time of treatment

          -  Unable to interrupt aspirin, other non-steroidal anti-inflammatory drugs

          -  Inability to take steroid premedications or vitamin supplementation

          -  The presence of active brain metastases

          -  Prior radiotherapy within 4 weeks prior to the first day of treatment

          -  Prior surgery within 3 weeks prior to the first day of treatment

          -  Prior chemotherapy within 3 weeks prior to the first day of treatment
Clinical trial NCT01925300 (phase 1, status: withdrawn)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: concor 5mg(bisoprolol hemifumarate 5mg) 2tab, crestor 20mg(rosuvastatin calcium 20.80mg) 1tab, concor 5mg 2t and crestor 20 mg 1tab
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male volunteers in the age between 20 and 55 years old(inclusive)

          -  Body mass index (BMI) in the range of 18.5 to 27 kg/m2(inclusive)

          -  Medically healthy with no clinically significant vital signs (sitting position blood
             pressure, pulse rate) (90 mmHg ≤ systolic blood pressure ≤ 150 mmHg, 60 mmHg ≤
             diastolic blood pressure ≤ 100 mmHg, 50 beats per minute ≤ pulse rate ≤ 100 beats per
             minute)

          -  Available for the entire study period

          -  Understand the requirements of the study and voluntarily consent to participate in the
             study

        Exclusion Criteria:

          -  Subjects with a history of gastrointestinal diseases which might significantly change
             ADME(Absorption, Distribution, Metabolism and Excretion) of medicines

          -  History of clinically significant arrhythmic, peripheral vascular,thyroid,
             bronchospasm, asthma disease

          -  Subjects with anaphylaxis to bisoprolol and/or rosuvastatin

          -  History of drug abuse

          -  History of caffeine, alcohol, smoking abuse

               -  caffeine(coffee,tea,coke) or grapefruit juice > 4cups/day

               -  smoking > 20 cigarettes/day

               -  alcohol > 140g/week

          -  Clinical laboratory test values are outside the accepted normal range

               -  AST(Aspartate Transaminase), ALT(ALanine Transaminase)( > 1.5 times to normal
                  range

               -  CK(Creatine Kinase) > 1.5 times to normal range

               -  Estimated GFR(Glomerular Filtration Rate) < 60 mL/min

          -  Subjects with whole blood donation within 60days, component blood donation within
             30days and blood transfusion within 30days prior to study medication dosing

          -  Subjects considered as unsuitable based on medical judgement by investigators
Clinical trial NCT00560352 (phase 1, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: dasatinib, bortezomib, dexamethasone
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Key Inclusion Criteria:

          -  Confirmed diagnosis of multiple myeloma with measurable disease

          -  Evidence of relapsed or refractory disease and at least 2 prior therapies for multiple
             myeloma

          -  Eastern Cooperative Oncology Group Performance Status of 0 - 2

          -  Last treatment for multiple myeloma not within 21 days prior to study treatment
             initiation

          -  Bone marrow transplant not within 3 months prior to study treatment initiation

          -  Required baseline hematology and chemistry parameters.

        Key Exclusion Criteria:

          -  Clinically significant cardiac disease (New York Heart Association Class III or IV)

          -  Abnormal QT interval corrected for heart rate using Fridericia's formula prolonged
             (>450 msec) after electrolytes have been corrected on baseline electrocardiogram

          -  Malabsorption syndrome or uncontrolled gastrointestinal toxicities

          -  Dementia, chronic medical or psychiatric condition, or laboratory abnormality that may
             increase the risk associated with study participation

          -  Clinically significant pleural effusion in the previous 12 months or current ascites

          -  Clinically significant coagulation or platelet function disorder

          -  Intolerance to dasatinib and/or bortezomib

          -  Acute diffuse infiltrative pulmonary disease

          -  Prior or concurrent malignancy, except for adequately treated basal cell or squamous
             cell skin cancer, adequately treated Stage I or II cancer currently in complete
             remission, cervical carcinoma in situ, or any other cancer from which the participant
             has been disease-free for 3 years.
Clinical trial NCT01273558 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: canagliflozin
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with T2DM who are not receiving treatment with any anti-hyperglycemic agents
             (AHAs) for at least 12 weeks, or who are receiving treatment with a stable dose and
             regimen of metformin monotherapy for at least 12 weeks and have a hemoglobin A1c
             (HbA1c) in the range of >=7% to <=10%

        Exclusion Criteria:

          -  History of Type 1, "brittle" diabetes or secondary forms of diabetes

          -  History of 1 or more severe hypoglycemic episodes

          -  History of diabetic complications considered to be clinically significant by the
             Investigator

          -  History of or current illness considered to be clinically significant by the
             investigator
Clinical trial NCT00730392 (phase 1/phase 2, status: completed)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: etanercept, placebo
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females subjects with T1DM aged 3-18 years

          -  Positive GAD 65 and/or islet cell antibody

          -  HbA1c at diagnosis above 6%

          -  Insulin regimen with 3 injection of insulin daily (as described below)

          -  White blood count between 3,000-10,000 and platelets > 100,000

          -  Normal ALT and AST, creatinine < 1.8 mg/dl

          -  T1DM duration equal or less than 4 weeks

        Exclusion Criteria:

          -  Infection requiring IV antibiotics at diagnosis or within past 14 days from study
             entry

          -  BMI over 85th percentile for age and gender

          -  Unstable household

          -  Unable to provide compliance with study drug, insulin and study visits,

          -  Evidence of psychiatric disease in the potential study subject and/or primary care
             taker

          -  And chronic diseases, including additional autoimmune disorders with the exception of
             euthyroid autoimmune thyroiditis
Clinical trial NCT00494221 (phase 1/phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: azd2171, folfox (5-fluorouracil, leucovorin, oxaliplatin), placebo cediranib
SMILES: COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic colorectal cancer

          -  WHO performance status 0-1

          -  Life expectancy is 12 weeks or longer

        Exclusion Criteria:

          -  Patient with uncontrolled brain metastases

          -  Patient with inappropriate laboratory tests values

          -  Patient with poorly controlled hypertension
Clinical trial NCT02012166 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: mk-0893 10 mg, mk-0893 40 mg, mk-0893 200 mg, mk-0893 1000 mg, placebo
SMILES: COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1, COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1, COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1, COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Good health

          -  Body Mass Index of between 18 and 28 kg/m^2, or up to 30 kg/m^2 with approval of
             sponsor

          -  Non-smoker for at least 6 months

          -  Willing to avoid strenuous physical activity

          -  Willing to avoid alcohol, caffeine, and grapefruit juice consumption

        Exclusion Criteria:

          -  History of renal, neurologic, gastrointestinal or respiratory disease or any
             gastrointestinal surgery

          -  History of multiple and/or severe allergies to a prescription, nonprescription or
             investigational drug or food

          -  History of any cardiovascular/cardiac disease

          -  History of any hepatic disease and primary biliary cirrhosis

          -  History of hypoglycemia or glucose intolerance, type 1 diabetes, or type 2 diabetes

          -  Requires or anticipates use of prescription or nonprescription medications, including
             herbal remedies

          -  A user of any illicit drugs or a history of drug or alcohol abuse

          -  Surgery, donated a unit of blood, or participated in another clinical study within 4
             weeks prior to study participation

          -  History of hypersensitivity to insulin, glucagon, or Sandostatine®.
Clinical trial NCT00543114 (phase 1, status: terminated)
Conditions: chronic lymphocytic leukemia, small lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10, A87.2, K52.832, D72.111, C91.11, C91.12, C91.10
Drugs: lenalidomide, fludarabine, rituximab
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    lack of efficacy and tolerability
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Diagnosed with B-CLL/SLL based on the standard histologic and immunophenotypic
             criteria described in the WHO classification

          -  No prior systemic therapy for CLL/SLL, including chemotherapy or antibody therapy

          -  Currently needs therapy based on 1996 NCI-WG criteria

          -  Measurable disease

          -  ECOG Performance Status of 0-2

          -  Laboratory test results within parameters outlined in protocol

          -  Able to take aspirin daily as prophylactic anticoagulation

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent document

          -  Pregnant or breast-feeding females

          -  Any condition, including the presence of abnormal laboratory abnormalities, which
             places the subject at unacceptable risk if he/she were to participate in the study

          -  Use of any other experimental drug or therapy within 28 days of baseline

          -  Known hypersensitivity to thalidomide

          -  Development of erythema nodosum characterized by a desquamating rash while taking
             thalidomide or similar drugs

          -  Prior use of lenalidomide

          -  Concurrent use of other anti-cancer agents or treatments

          -  Known positive for HIV

          -  Chronic active Hep B patients not on prophylactic lamivudine

          -  Diagnosis of Mantle Cell Lymphoma
Clinical trial NCT01192165 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: trametinib (gsk1120212), docetaxel, erlotinib, pemetrexed, carboplatin, nab-paclitaxel, cisplatin
SMILES: CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  The subject has a solid tumor. Expansion cohorts are limited to non-small cell lung
             cancer and/or pancreatic cancer with or without a KRAS mutation.

          -  Tumor progression following at least one prior standard therapy, the subject refuses
             standard therapy, or no standard therapy exists.

          -  The subject has a radiographically measurable tumor.

          -  The subject is able to carry out daily life activities without difficulty.

          -  The subject is able to swallow and retain oral medication.

          -  The subject does not have significant side effects from previous anti-cancer
             treatment.

          -  The subject has adequate organ and blood cell counts.

          -  Sexually active subjects must use medically acceptable methods of contraception during
             the course of the study.

        Exclusion Criteria:

          -  The subject has had major surgery or received certain types of cancer therapy within
             2-3 weeks before starting the study.

          -  The subject has a brain tumor.

          -  Current severe, uncontrolled systemic disease.

          -  History of clinically significant heart, lung, or eye/vision problems.

          -  The subject has high blood pressure that is not well-controlled with medication.

          -  The subject has a permanent pacemaker.

          -  The subject is pregnant or breastfeeding.

          -  Positive for Hepatitis B, Hepatitis C, or HIV.
Clinical trial NCT00612794 (phase 1, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide once weekly, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Body weight ≥50 kg.

          -  Have suboptimal glycemic control as evidenced by an HbA1c defined by the following
             criteria: *6.5% to 10.0%, inclusive, at study start for patients managed with diet
             modification and exercise or treated with oral antidiabetics drug but not alpha
             glucosidase inhibitor or meglitinide derivatives; *6.5% to 9.5%, inclusive, at study
             start for patients treated with oral antidiabetics including alpha glucosidase
             inhibitor or meglitinide derivatives.

          -  Have been treated with diet modification and exercise alone or in combination with a
             stable regimen of oral antidiabetic drugs (sulfonylurea, metformin and
             thiazolidinedione) for at least 2 months prior to study start. In the case of patients
             with concomitant use of sulfonylurea, the dose of sulfonylurea must not be more than
             maximum recommended dose. The patients with concomitant use of alpha glucosidase
             inhibitors (Glucobay® [acarbose], Basen® [voglibose], or Seibule® [miglitol]) or
             meglitinide derivatives (Glufast® [mitiglinide] or Fastic®/Starsis® [nateglinide]) can
             be included in this study, but these drugs must be discontinued after confirmation of
             eligibility at study start.

        Exclusion Criteria:

          -  Subjects who have donated more than 200 mL of blood and component blood donation
             within one month of study start, or those who have donated more than 400 mL of blood
             within three months of study start.

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.

          -  Have participated and received at least one dose of exenatide or other GLP-1 analogs
             in this study previously, or any other study using exenatide or other GLP-1 analogs.

          -  Are treated with any exogenous insulin within 3 months of screening.

          -  Are continuously treated with any of the following excluded medications within 3
             months of screening (more than 7 days per 1 month): *Drugs that directly affect
             gastrointestinal motility, including Nauzelin® (domperidone), Primperan®/Terperan®
             (metoclopramide), Ganaton® (itopride), Acenalin® (cisapride), Gasmotin® (mosapride),
             or Cerekinon® (trimebutine).

          -  Females who are breastfeeding.